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OSTEOARTHRITIS BIOLOGY
A.-M. Malfait. Rush Univ. Med. Ctr., Chicago, IL, USA
Purpose: To review original research papers on the topic of Osteo-
arthritis (OA) Biology, published in peer-reviewed journals since Jan-
uary 2014.
Methods: A Pubmed Search was conducted using combinations of the
terms “osteoarthritis”, “cartilage”, “subchondral bone”, “synovium”,
“meniscus”, “joint”, “inﬂammation”, “pain”, “risk factors”, “ageing”,
“obesity”, and “animal models”.
Results: Research continues to focus on the biology of joint tissues,
including cartilage, subchondral bone, synovium, meniscus, and
increasingly also muscle and nerves. Emerging themes over the past
year include: 1) Focus on pathways and mechanisms that may be spe-
ciﬁc to subtypes of OA and to risk factors such as ageing and obesity; 2)
The role of inﬂammation in different subtypes of OA; 3) Mechanisms of
joint pain. Selected in vitro and in vivo studies of relevance to OA
biology will be highlighted.
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CLINICAL
L. Sharma. Feinberg Sch. of Med., Northwestern Univ., Chicago, IL, USA
The purpose of this review is to highlight research in osteoarthritis,
particularly in the realms of epidemiology, observational studies,
pharmacologic treatment, and non-pharmacologic interventions and
strategies. A literature search was conducted using PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/) with the search terms “osteo-
arthritis [All Fields] AND treatment [All Fields]” and the following limits
activated: humans, English language, all adult 19þ years, published
between April 1, 2014 and February 10, 2015 (to prepare this abstract;
updated search ﬁndings will be presented). This search identiﬁed 538
articles. A second literature search was then conducted with the search
terms “osteoarthritis [All Fields] AND epidemiology [All Fields]”, with
the same limits; this search identiﬁed a total of 146 articles. Reports of
surgical outcome, case series, surgical technique, tissue sample or cul-
ture studies, trial protocols, and pilot studies were excluded.
Of 684, 128 were considered relevant. Among epidemiologic and
observational studies, themes included: physical activity (e.g., associa-
tion with incident knee OA, association with joint pain and stiffness,
factors associated with activity avoidance, impact of sedentary activity,
effect of walking on incident function limitation, qualitative analysis of
symptom impact on activity, impact of time in light intensity activity on
disability outcomes, association with health-related utility); early knee
OA, (e.g., ﬁrst activities to become painful in knee OA, prediction of early
knee OA, signiﬁcance of minor radiographic features, signiﬁcance of
pre-radiographic MRI lesions, impact of rapid radiographic change in
early OA); pain (e.g., mechanisms, trajectories, risk proﬁles); con-
ﬁdence/instability/falls (e.g., fall risk in OA, factors associated with knee
conﬁdence, combined impact of falls and OA on function); hand OA
(e.g., inﬂammatory features and hand OA progression, association
between MRI-based tissue lesions and progression and erosion devel-
opment, hand OA and coronary heart disease events, correlates of pain
in hand OA, erosive OA as a more severe form of disease, prevalence and
burden of CMC OA); foot OA (e.g., prevalence of associated disability,
factors associated with 1st MTP OA severity, impact of foot pain on
health and function). Symptom outcomes of pharmacologic treatments
were reported for methotrexate, adalimumab, anti-nerve growth factor
monoclonal antibodies, strontium ranelate, bisphosphonates, glucos-
amine, and chondroitin sulfate, and structural outcomes for strontium
ranelate, recombinant human ﬁbroblast growth factor 18, and glucos-
amine and chondroitin sulfate. Reviews included a Cochrane review of
topical rubefacients containing salicylates for chronic conditions and
systematic review and network meta-analysis to analyze comparative
effectiveness of pharmacologic interventions for knee OA. Symptom
outcomes of non-pharmacologic interventions were reported for:
neuromuscular exercise, quadriceps strengthening, weight reduction
and maintenance, TENS, therapeutic ultrasound, stepped care strat-
egies, cognitive behavior therapy for sleep disturbance, acupuncture,
gait modiﬁcation, booster physical therapy, a web-based therapeutic
exercise resource center for knee OA; hip physical therapy for hip OA;
and joint protection and hand exercises for hand OA. Additional studies
reported on the acute biomechanical effects of lateral wedge insoles.
Structure outcomes of non-pharmacologic interventions were reportedfor patellofemoral bracing and weight loss. Reviews included meta-
analyses of exercise, valgus bracing, ginger, electrical stimulation, and
continuous and pulsed ultrasound.
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OSTEOARTHRITIS GENETICS AND GENOMICS: STATUS AND FUTURE
PERSPECTIVES
U. Styrkarsdottir. deCODE Genetics, Reykjavík, Iceland
An overview of the recent progress in genetics of osteoarthritis will be
presented and discussed in relation to advances in human genetics
studies in general.
Genome-wide SNP association (GWA) studies have been impressively
successful at discovering sequence variations that contribute to com-
plex human diseases. Replication of ﬁndings in independent sample
sets and populations has become the standard practice in GWA studies,
greatly minimizing the risk of spurious ﬁndings which were common in
small scale candidate gene studies. Meta-analysis of GWA studies fur-
ther capitalize on increased power by analyzing results from several
studies together and have dramatically increased the number of loci
found to associate with many diseases. The SNPs analyzed in GWA
studies are common (until recently) and, therefore, only confer a small
risk/effect on the phenotypes. They generally explain only a small
portion of the heritability of a disease. Finding, and understanding, the
remaining part of the heritability currently represents the main chal-
lenge of human genetics. Researchers emphasize whole genome
sequencing (WGS) efforts, which offer an opportunity to study all var-
iations in the genome of an individual and to ﬁnd rare variants of large
effect. Other mechanisms are also being studied as contributing factors.
This presentation will focus on recent results of GWA, WGS and meta-
analyses studies in osteoarthritis. Particular attentionwill be paid to the
importance of sample size, phenotype, replications, collaborations and
large scale analyses as illustrated by studies on other human diseases
and traits such as height, bone density and diabetes.
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OSTEOARTHRITIS YEAR IN REVIEW: IMAGING
F. Cicuttini. Monash Univ., Melbourne, Australia
Purpose: To review recent original research publications related to of
osteoarthritis and to identify trends and advances.
Methods: Medline/PubMed databases were examined to identify rele-
vant articles. The search terms included “osteoarthritis” combined with
“ ”, and either “radiography”, “MRI”, “ultrasound”, “computed tomog-
raphy”, or “nuclear medicine.” Articles published, or in Press, between
January 2014 and January 2015 were included. Abstracts were reviewed
to exclude review articles and case reports.
Results: 471 references were identiﬁed (217 human studies). Of the
human studies, MRI (144) and radiography (83) were the most common
primary modalities in OA studies, while CT ( 45 ), ultrasound (17) and
nuclear medicine (7) were less commonly used. Most studies are still
focused on the knee (131), although increasing numbers of studies are
examining the hip (30) and hands (15). Most MRI studies continue to be
focused on cartilage, either as the outcome measure, or in the devel-
opment of improved MRI parametric mapping techniques. Few studies
have examined the back (6).
Conclusions: continues to have a major role in osteoarthritis research.
Although use of MRI outcomes measures is largely established for
epidemiological studies at the knee, the lessons learnt are being steadily
translated to other joints such as the hand and hip. Other modalities,
such as ultra-sound and CT provide important, complementary infor-
mation. There remain joint groups with large burden of disease, such as
the back, where little work is currently underway.
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SOLUBLE BIOMARKERS; THERE IS TILL A NEED FOR OA BIOMARKERS
A.C. Bay-Jensen. Nordic BioSci., Biomarker and Res., Herlev, Denmark
There is still a need for robust and validated biomarkers for preclinical,
early clinical and clinical development of novel disease modifying OA
drugs (DMOADs) for osteoarthritis (OA). In other words there is still
room for more biomarkers that can be used as 1) pharmaco-dynamic
and early mode of action biomarkers in in vitro, ex vivo and in vivo
models, 2) biomarkers for early identiﬁcation of efﬁcacy, 3) tools for
